Patents by Inventor Robert Eisenthal

Robert Eisenthal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8349583
    Abstract: A method for detecting the absence or presence of cells of interest in a liquid sample is provided. The method comprises providing a sample suspected of containing cells of interest that contain an intracellular enzyme with a measurable activity. The sample further comprises an extracellular medium that also includes an extracellular enzyme with the measurable activity. The method further comprises the steps of treating the liquid sample with a reagent that inactivates the measurable activity in the extracellular medium but does not inactivate the measurable activity in the cells of interest, lysing the cells of interest to release the intracellular enzyme, and measuring the measurable activity. Thus, the measurable activity of the intracellular enzyme can be measured without interference from the extracellular enzyme. The invention is particularly useful for treatment of bacterially-infected blood using a detection assay based on adenylate kinase activity.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: January 8, 2013
    Assignee: 3M Innovative Properties Company
    Inventors: Marc Green, Robert Eisenthal, Janet Eisenthal, legal representative
  • Publication number: 20090275063
    Abstract: A method for detecting the absence or presence of cells of interest in a liquid sample, wherein: (a) the sample: (i) comprises an extracellular medium containing an enzyme with a measurable activity; and (ii) is suspected of containing cells of interest that contain an enzyme with said measurable activity; and (b) the method comprises the steps of: (i) treating the liquid sample with a reagent that inactivates said measurable activity in the extracellular medium, but does not inactivate the measurable activity in said cells of interest; (ii) lysing the cells of interest to release the intracellular enzyme; and (iii) measuring said measurable activity. Thus the intracellular enzyme can be measured without interference from the extracellular enzyme. The invention is particularly useful for treatment of bacterially-infected blood using a detection assay based on adenylate kinase activity.
    Type: Application
    Filed: May 3, 2006
    Publication date: November 5, 2009
    Inventors: Marc Green, Robert Eisenthal
  • Publication number: 20040120938
    Abstract: A formulation for use as a bactericidal agent in the human or animal digestive system includes xanthine oxidoreductase. The formulation may especially be in the form of a formula feed formulation or enteral feed formulation for administration to a human or animal. The formulation is capable of functioning as a “natural antibiotic” to prevent or reduce bacterial infection within the gut, especially the neonatal gut.
    Type: Application
    Filed: December 10, 2003
    Publication date: June 24, 2004
    Applicant: The University of Bath
    Inventors: David Russell Blake, Clifford Robert Stevens, Robert Eisenthal, Roger Harrison, Timothy Marc Miller, Rachel Edwards
  • Patent number: 6682732
    Abstract: A composition for use in the treatment of lesions of the human or animal body comprises xanthine oxidoreductase and a pharmaceutically acceptable electron donor system. The composition can accelerate wound healing, especially in a hypoxic environment.
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: January 27, 2004
    Assignee: The University of Bath
    Inventors: David Russell Blake, Clifford Robert Stevens, Robert Eisenthal, Roger Harrison, Timothy Mark Millar, Tulin Bodamyali, Janos Kanczler